However, the CD83 maturation marker was expressed in a considerably lower percentage (16.68 ± 7.73% vs. 45–50%), suggesting that melanoma patients’ LCs migrate from the skin to SLNs, preserving immature phenotype, possibly tolerating melanoma-associated antigens and promoting cancer spread [45]. The gene discussed is CD83; the disease is cancer.